References of "Geusens, P"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailWhat are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Osteoporosis International (2012, March), 23(S2), 81-82

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailQuelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Revue du Rhumatisme (2012), 79(S1), 238

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailNominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Annals of the Rheumatic Diseases (2012), 71(3), 597

Detailed reference viewed: 30 (5 ULg)
Full Text
Peer Reviewed
See detailA prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip
Luyten, F. P.; Geusens, P.; Malaise, Michel ULg et al

in Annals of the Rheumatic Diseases (2007), 66(1), 99-106

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised, double-blind ... [more ▼]

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised, double-blind, placebo-controlled study, patients were randomly assigned to receive continuous (n = 62) or intermittent (n = 61) treatment with celecoxib 200 mg once daily. The primary efficacy end point was the area under the curve (AUC) of the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total scores between baseline and week 24 divided by the time interval. Secondary end points included the percentage of days with intake of the flare drug, the AUC of the change in the WOMAC total scores, the mean change from baseline in the WOMAC scores, and the patient's and physician's global assessment of osteoarthritis. Results: There were no significant differences between patients randomised to continuous or intermittent treatment in the primary end point or most of the secondary end points, although a consistent trend supporting continuous treatment was observed. The percentage of days with intake of the flare drug was significantly lower (p = 0.031) in the group receiving continuous versus intermittent celecoxib. Both treatment regimens were well tolerated. Conclusion: The results of this pilot study indicate a potential clinical difference between continuous and intermittent treatment with celecoxib, and may be useful in designing future trials. A larger trial on both efficacy and safety outcomes is required for conclusive evidence in favour of either continuous or intermittent treatment. [less ▲]

Detailed reference viewed: 22 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of risedronate on the risk of hip fracture in elderly women
McClung, MR; Geusens, P; Miller, PD et al

in Clinical Rheumatology (2001), 20

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
McClung, M R; Geusens, P; Miller, P D et al

in New England Journal of Medicine [=NEJM] (2001), 344(5), 333-40

BACKGROUND: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. METHODS: We studied 5445 women 70 to 79 years old who had osteoporosis ... [more ▼]

BACKGROUND: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. METHODS: We studied 5445 women 70 to 79 years old who had osteoporosis (indicated by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak value in young adults [-4] or lower than -3 plus a nonskeletal risk factor for hip fracture, such as poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than -4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The women were randomly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three years. The primary end point was the occurrence of hip fracture. RESULTS: Overall, the incidence of hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percent among those assigned to placebo (relative risk, 0.7; 95 percent confidence interval, 0.6 to 0.9; P=0.02). In the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo (relative risk, 0.6; 95 percent confidence interval, 0.4 to 0.9; P=0.009). In the group of women selected primarily on the basis of nonskeletal risk factors (those at least 80 years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to placebo (P=0.35). CONCLUSIONS: Risedronate significantly reduces the risk of hip fracture among elderly women with confirmed osteoporosis but not among elderly women selected primarily on the basis of risk factors other than low bone mineral density. [less ▲]

Detailed reference viewed: 13 (11 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis with a rapid and sustained effect
Silverman, S; Geusens, P; Bensen, W et al

in Arthritis and Rheumatism (2000), 43(S1), 781

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss with oral tiludronate
Roux, C; DEROISY, Rita ULg; Basse-Cathalinat, B et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailTiludronate and osteoporosis: further evidence of safety and efficacy
Reginster, Jean-Yves ULg; Ohnishj, H; Murakami, H et al

in Journal of Bone and Mineral Research (1994), 9(S1), 199

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailEvaluation of efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, dose-ranging, placebo-controlled study
Reginster, Jean-Yves ULg; Colson, F; Morlock, G et al

in Arthritis and Rheumatism (1993), 36

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailEvidence that tiludronate is an interesting perspective for prevention and treatment of postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Ethgen, D; Barbier, A et al

in Journal of Bone and Mineral Research (1993), 8(S1), 326

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailOral Tiludronate: a new perspective for prevention and treatment of postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Ethgen, D; Barbier, A et al

in Calcified Tissue International (1993), 52(S2), 30

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the Efficacy and Safety of Oral Tiludronate in Paget's Disease of Bone. A Double-Blind, Multiple-Dosage, Placebo-Controlled Study
Reginster, Jean-Yves ULg; Colson, F.; Morlock, G. et al

in Arthritis & Rheumatism : Arthritis Care & Research (1992), 35(8), 967-74

OBJECTIVE. To assess the optimal dosage of oral tiludronate in Paget's disease of bone. METHODS. We studied 149 patients with Paget's disease, in a double-blind, randomized, placebo-controlled trial ... [more ▼]

OBJECTIVE. To assess the optimal dosage of oral tiludronate in Paget's disease of bone. METHODS. We studied 149 patients with Paget's disease, in a double-blind, randomized, placebo-controlled trial. Patients were randomly assigned to 1 of 5 therapeutic groups: a daily dose of 100 mg, 200 mg, 400 mg, or 800 mg of oral tiludronate, or a placebo. Treatment was for 3 months, followed by 3 months of placebo-controlled followup. Serum alkaline phosphatase activity (SAP) and fasting urinary excretion of hydroxyproline/creatinine (OH/Cr) were measured monthly, as were biochemical parameters reflecting renal, hepatic, and hematologic functions. Analgesic efficacy was self-evaluated from a visual analog scale and a global pain index. RESULTS. Statistical analysis revealed that beginning at a dosage of 200 mg/day, there was a direct dose-dependent effect on the reduction of SAP and OH/Cr levels. Reduction of SAP levels was clinically significant at a dosage of 400 mg (44.9 +/- 4.2% reduction at 90 days and 49.2 +/- 4.5% at 180 days, mean +/- SEM) and at 800 mg (53.4 +/- 5% at 90 days and 59.3 +/- 4.6% at 180 days). There was a significant reduction in pain in all groups, including the group taking placebo. In only those taking 800 mg/day of tiludronate was there a significant frequency of complete resolution of pain (versus placebo). Aside from mild gastrointestinal disturbances, as experienced with other oral bisphosphonates, clinical tolerance of all 5 regimens was good. Exhaustive biochemical investigations failed to reveal significant toxicity of tiludronate up to the 800-mg daily dose investigated. CONCLUSION. Because of its significantly better antiresorptive effects and greater analgesic properties (compared with lower dosages), combined with the excellent clinical and biochemical tolerance, the 800-mg daily dose of tiludronate appears to be optimal for the treatment of Paget's disease of bone. [less ▲]

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailIn Vivo Long-Term Precision of Spinal Bone Mass Measurement by Dual Photon Absorptiometry
Reginster, Jean-Yves ULg; Geusens, P.; Nijs, J. et al

in Bone and Mineral (1989), 6(2), 225-9

Detailed reference viewed: 3 (1 ULg)